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BACKGROUND: Orai1 is a critical ion channel subunit, best recognized 
as a mediator of store-operated Ca2+ entry (SOCE) in nonexcitable cells. 
SOCE has recently emerged as a key contributor of cardiac hypertrophy 
and heart failure but the relevance of Orai1 is still unclear.
METHODS: To test the role of these Orai1 channels in the cardiac 
pathophysiology, a transgenic mouse was generated with cardiomyocyte-
specific expression of an ion pore-disruptive Orai1R91W mutant (C-dnO1). 
Synthetic chemistry and channel screening strategies were used to 
develop 4-(2,5-dimethoxyphenyl)-N-[(pyridin-4-yl)methyl]aniline (hereafter 
referred to as JPIII), a small-molecule Orai1 channel inhibitor suitable for in 
vivo delivery.
RESULTS: Adult mice subjected to transverse aortic constriction (TAC) 
developed cardiac hypertrophy and reduced ventricular function 
associated with increased Orai1 expression and Orai1-dependent 
SOCE (assessed by Mn2+ influx). C-dnO1 mice displayed normal cardiac 
electromechanical function and cellular excitation-contraction coupling 
despite reduced Orai1-dependent SOCE. Five weeks after TAC, C-dnO1 
mice were protected from systolic dysfunction (assessed by preserved left 
ventricular fractional shortening and ejection fraction) even if increased 
cardiac mass and prohypertrophic markers induction were observed. This 
is correlated with a protection from TAC-induced cellular Ca2+ signaling 
alterations (increased SOCE, decreased [Ca2+]i transients amplitude and 
decay rate, lower SR Ca2+ load and depressed cellular contractility) and 
SERCA2a downregulation in ventricular cardiomyocytes from C-dnO1 
mice, associated with blunted Pyk2 signaling. There was also less fibrosis 
in heart sections from C-dnO1 mice after TAC. Moreover, 3 weeks 
treatment with JPIII following 5 weeks of TAC confirmed the translational 
relevance of an Orai1 inhibition strategy during hypertrophic insult.
CONCLUSIONS: The findings suggest a key role of cardiac Orai1 channels 
and the potential for Orai1 channel inhibitors as inotropic therapies for 
maintaining contractility reserve after hypertrophic stress.
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Despite significant management and therapeutic advances, heart failure (HF) still represents an epidemic threat, highlighting the need to deeper 
understand the cellular mechanisms involved in the 
pathogenesis in order to identify new molecular targets 
and develop innovative therapeutic strategies.
Recent studies reported that store-operated Ca2+ en-
try (SOCE) dysfunction contributes to the development 
of pathological cardiac hypertrophy and HF.1,2
The Orai1 protein (calcium release-activated calcium 
channel protein 1) has been proposed as the prototype 
of the pore-forming subunit of the plasmalemmal store-
operated Ca2+ channels.3 While in nonexcitable cells 
Orai1/STIM1 (stromal interaction molecule 1)-mediated 
SOCE and its long-term pathophysiological outcomes 
have been relatively easier to pinpoint, its role in the 
heart is less clear. Orai1 and STIM1 have been detected 
in rodents and human heart.4–6 Orai1/STIM1-mediated 
SOCE appears to be developmentally regulated in the 
heart, with prominent activity in developing cardio-
myocytes7 and plays a role in maintaining ventricular 
diastolic Ca2+ homeostasis that is crucial for postnatal 
cardiac growth.4,8,9 However, while Orai1-deficient ze-
brafish developed spontaneous HF,5 global heterozy-
gous Orai1+/- mice showed normal systolic function at 
baseline but developed more severe dilated cardiomy-
opathy after pressure overload insult.10
On the other hand, in vitro data showed Orai1 up-
regulation after hypertrophic stress and demonstrated 
that Orai1 silencing is associated with protection from 
hypertrophy via reduced calcineurin (CaN) activity.4,11 
Likewise, it has been recently reported that in vivo over-
expression of SOCE-associated regulatory factor in the 
heart prevents cardiac hypertrophy probably through 
suppressing the upregulation of STIM1 and Orai1.12
Consequently, the question remains whether this 
deleterious effect is related to developmental or adult 
systemic or cardiac specific alteration. Overall, the con-
tribution of Orai1 to Ca2+ homeostasis and cardiac 
function remains elusive and conflicting.
The goal of the present study was to use novel tools 
to determine whether the cardiac Orai1-dependent 
pathway contributes to the electromechanical phe-
notype of ventricular cardiomyocytes using 2 inde-
pendent approaches: (1) a genetic mouse model with 
cardiomyocyte-specific expression of the dominant-
negative dn-Orai1R91W mutant (C-dnO1) resulting in 
abolished store-operated Ca2+ channel function; and 
(2) pharmacological blockade by a novel Orai1 inhibi-
tor, 4-(2,5-dimethoxyphenyl)-N-[(pyridin-4-yl)methyl]
aniline (hereafter referred to as JPIII), which is suitable 
for in vivo use.
Our findings support the idea that Orai1 inhibition 
can improve Ca2+ cycling and systolic cardiac function 
during hypertrophic stress, suggesting that selective 
Orai1 blockade might provide a new therapy for cardiac 
hypertrophy and HF.
METHODS
All data and materials supporting the findings of this study are 
available in the article and its online-only Data Supplement or 
from the corresponding authors upon reasonable request.
All experiments were performed according to the ethical 
principles set by the French Ministry of Agriculture (agreement 
D-92–019-01) and the UK Scientific Procedures Act (1986) 
and were performed in accordance to the guidelines from 
Directive 2010/63/EU of the European Parliament on the pro-
tection of animals. Animal studies were approved by the local 
Ethics Committee (CREEA Ile-de-France Sud or Leeds Animal 
Welfare and Research Ethics Board and UK Home Office [PPL 
40/3557 and P606320FB]).
Detailed descriptions of all materials and methods used in 
this study, including chemicals, generation of C-dnO1 trans-
genic mice, ventricular myocytes isolation, cell culture, Orai1 
knockdown in pulmonary arterial smooth muscle cells, gen-
eration of Orai1 deficient fibroblasts, blue-gal staining, quan-
titative reverse transcription polymerase chain reaction with 
specific primers (Table I in the online-only Data Supplement), 
western blot with used antibodies (Table II in the online-only 
Clinical Perspective
What Is New?
• Whereas store-operated Ca2+ entry has recently 
gained attention in cardiac pathophysiology, the 
role of the prototypic store-operated channel, 
Orai1 remains elusive.
• Using a novel genetically-modified mouse that 
specifically disrupts the Orai1 channel in cardiomy-
ocytes, we showed that even if Orai1 is not instru-
mental in regulating normal excitation-contraction 
coupling and cardiac function, its functional inhi-
bition preserves alterations of Ca2+ homeostasis, 
fibrosis and systolic function without affecting 
hypertrophy during pressure overload.
• JPIII, a novel in vivo–suitable small-molecule Orai1 
channel inhibitor, markedly improves left ventricu-
lar systolic function and Ca2+ handling after pres-
sure overload without causing adverse effect.
What Are the Clinical Implications?
• Ca2+ effectors have a major impact on cardiac 
hypertrophic signaling.
• We provide an important breakthrough that inhib-
iting Orai1 function in the heart could be beneficial 
after insult by protecting it against progressive left 
ventricular systolic dysfunction.
• Our results suggest that Orai1 inhibition has a 
potential favorable hemodynamic value to protect 
the heart from maladaptive hypertrophy and might 
represent a new inotropic support to help to relieve 
systolic dysfunction.
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Data Supplement), immunostaining, immunohistochemistry 
of heart sections, histological analysis of cardiac fibrosis, mea-
surement of cation influx using Fura-2 fluorescence quench-
ing by MnCl2, Ca
2+ imaging, high throughput Ca2+ imaging, 
action potential recording, patch-clamp recording, telemet-
ric electrocardiogram studies, transverse aortic constriction, 
echocardiography, tail cuff plethysmography, liquid chroma-
tography–mass spectrometry for JPIII, in vitro ADMET, in vivo 
chronic treatment, chemical synthesis are presented in online-
only Data Supplement.
Statistical Analysis
The number of cells (n) or animal (N) studied per experiment 
is indicated. Data are presented as mean±SEM. Statistical 
analyses were performed with Student t test, 1-way or 
2-way ANOVA followed by post hoc Fisher LSD test for mul-
tiple comparisons, as stated in figures and tables legends, 
using GraphPad Prism 6.0 software. The equality of variance 
assumption was tested using an F-test and Brown-Forsythe 
test for the t test and ANOVA, respectively. All the assump-
tions of the equal variances were met. A value of P<0.05 was 
considered significant.
RESULTS
Increased Orai1 Channel Expression 
and Activity After Transverse Aortic 
Constriction
To determine whether Orai1 channels are involved in 
the pathological stress response, adult wild-type (WT) 
mice were subjected to transverse aortic constriction 
(TAC). After 5 weeks, mice showed clear left ventricu-
lar dysfunction and structural abnormalities compared 
with age-matched sham-operated mice, as assessed 
by morphometric and echocardiographic parameters 
(Tables 1 and 2). This was associated with an increase in 
Orai1 expression at both mRNA (Figure 1A) and protein 
(Figure 1B) in ventricular tissues. Orai1 antibody speci-
ficity was validated by western blot analysis using the 
Orai1 blocking peptide in the presence of the antibody 
(Figure Ia in the online-only Data Supplement), siRNA 
knockdown of Orai1 in human pulmonary arterial 
smooth muscle cells (Figure Ib in the online-only Data 
Supplement), knockout of Orai1 in fibroblasts isolated 
from Orai1fl/fl mice exposed to ex vivo TAT-Cre (Figure Ic 
through If in the online-only Data Supplement), and by 
immunohistochemistry using the blocking peptide (Fig-
ure Ig and Ih in the online-only Data Supplement). Im-
munohistochemistry of ventricular sections from sham 
and TAC-operated mice showed Orai1 localization at 
the plasma membrane as indicated by colocalization 
with the surface membrane marker, wheat germ ag-
glutinin (Figure 1C). Furthermore, we performed coim-
munostaining of Orai1 with the cardiomyocyte marker, 
α-actinin, demonstrating Orai1 expression in cardiomy-
ocytes (Figure Ii in the online-only Data Supplement). 
Analysis of the Orai1 fluorescence signal in isolated 
cardiomyocytes from sham-operated and TAC mice re-
vealed a colocalization between Orai1 and wheat germ 
agglutinin (Figure 1D), which was increased after TAC 
(Figure 1E), whereas no striated pattern was found in 
comparison to α-actinin staining (Figure II in the online-
only Data Supplement).
TRPC6 (transient receptor potential canonical 6), 
Orai3 and STIM2 mRNA and protein levels were also 
upregulated (Figure III in the online-only Data Supple-
ment) while TRPC1, -C3, -C4, -C5, STIM1 and Orai2 
proteins were unchanged after TAC (Figure IV in the 
online-only Data Supplement). Freshly isolated ven-
tricular cardiomyocytes from TAC mice showed a ro-
bust store-operated cation entry following Ca2+ store 
depletion compared with ventricular cardiomyocytes 
from sham-operated mice, as demonstrated by a fast-
er reduction of fluorescence decay upon addition of 
Mn2+ in the presence of major Ca2+ entry pathways 
inhibitors (Figure 1F).
We developed a novel Orai1 small-molecule inhibi-
tor, JPIII, based on the Synta66 scaffold (Figure Va in the 
online-only Data Supplement),13 which is known to be 
both potent and selective but with poor aqueous solu-
bility limiting in vivo use. JPIII exhibited nanomolar po-
tency against endogenous SOCE in HEK293 cells (Figure 
Va in the online-only Data Supplement) and was highly 
Table 1. Morphometric Analysis Under Stressed Condition
Morphometric 
Analysis
WT C-dnO1 P Value
Sham (N=17) TAC (N=15) Sham (N=15) TAC (N=16)
WT Sham vs 
WT TAC
WT Sham vs 
C-dnO1 Sham
C-dnO1 Sham  
vs C-dnO1 TAC
WT TAC vs 
C-dnO1 TAC
Body weight, g 26.0±0.5 26.0±0.9 25.0±0.5 25.8±0.4 0.99 0.24 0.35 0.81
Heart weight, mg 165±3 247±15 171±12 240±16 0.0001 0.73 0.0002 0.69
Heart weight/body 
weight, mg/g
6.4±0.2 9.7±0.8 6.8±0.3 9.4±0.7 0.0001 0.61 0.001 0.70
Tibia length, mm 17.5±0.1 17.7±0.1 17.7±0.1 17.9±0.1 0.16 0.16 0.17 0.17
Heart weight/tibia 
length, mg/mm
9.4±0.2 14.0±0.9 9.7±0.7 13.4±0.9 0.0001 0.77 0.0006 0.56
Statistical significance was evaluated using a 2-way ANOVA, then by a post hoc Fisher least significant difference test for multiple comparisons (reported P values). 
TAC indicates transverse aortic constriction; and WT, wild type.
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effective against SOCE in HEK293 cells transiently overex-
pressing Orai1/STIM1 (Figure Vb in the online-only Data 
Supplement) or a self-activating Orai1-SS chimera (Figure 
Vc in the online-only Data Supplement). Electrophysio-
logical recordings in Orai1-transfected HEK293 cells also 
confirmed that JPIII is a potent Orai1 inhibitor with an IC50 
of 244 ± 39 nM (Figure Vd in the online-only Data Sup-
plement). Of note, JPIII did not modify activity of Orai3, 
TRPC5, TRPC6, TRPC4/C1, TRPC5/C1, or TRPM2 overex-
pressed in HEK293 cells (Figure VI in the online-only Data 
Supplement) suggesting Orai1 selectivity. Furthermore, 
in vitro assessment of pharmacokinetics (Figure VII in the 
online-only Data Supplement) supported suitability for in 
vivo delivery, although the relatively short half-life in mu-
rine liver microsomes suggested a need for continuous 
infusion during the in vivo studies.
JPIII (5 μM) significantly reduced depletion-induced 
cation entry in isolated ventricular cardiomyocytes from 
both sham- and TAC-operated mice (Figure  1F). Of 
note, the JPIII-sensitive cation entry in sham-operated 
mice was relatively small, consistent with a low level of 
Orai1 expression in adult rodent cardiomyocytes.5,14,15 It 
Figure 1. TAC induces increased Orai1 expression and enhanced store-operated cation entry after 5 weeks.  
A, Orai1 mRNA expression was determined by real-time quantitative polymerase chain reaction in ventricular tissue from sham-operated or transverse aortic con-
striction (TAC)-operated mice after 5 weeks. mRNA levels were normalized to housekeeping genes and expressed as fold change of that determined in sham mice. 
N=5–6 animals. ***P<0.001 vs sham mice. B, Top panel: representative western-blot of Orai1 in ventricular tissue from sham and TAC mice. Bottom panel: relative 
Orai1 protein expression was evaluated by western-blot. Protein levels were normalized by β-actin and expressed as fold change of that determined in sham mice. 
N=5 animals. ***P<0.001 vs sham mice. C, Left panel: representative immunohistochemistry with antibodies against Orai1 (red), WGA (wheat germ agglutinin; 
green) and nuclei (blue) showing Orai1 expression in mouse ventricular sections in sham and TAC conditions. Scale bar, 25 μm. Right panel: profile analysis from 
the whole transverse image demonstrates colocalization with WGA in peripheral regions. D, Representative immunostaining of Orai1 (red) and WGA (green) 
in ventricular cardiomyocytes from sham (top panel) or TAC (bottom panel) mice. Insets represent 2-fold magnification of main images. Profile analysis demon-
strates colocalization with WGA in peripheral regions. White lines across ventricular cells (in transverse axis) show examples of regions from which pixel counts 
were taken. Scale bar, 25 μm. E, Quantification of Orai1 immunostaining in ventricular cells from sham and TAC mice. N=3 animals. n=85–92 investigated cells. 
***P<0.001 vs sham mice. F, Left panel: representative fluorescence traces of the Fura-2 decay phase upon Mn2+ addition in cardiomyocytes from sham (light 
blue trace) and TAC (dotted light blue trace) mice in presence or absence of 5 µM JPIII, a new selective Orai1 inhibitor: sham (yellow trace) and after TAC (dotted 
yellow trace). Right panel: the initial slope of the Mn2+-induced decrease of Fura-2 fluorescence was fitted by linear regression and averaged (ΔF/dt, %/min) were 
presented on bar graph for cardiomyocytes from sham and TAC mice in presence or absence of 5 µM JPIII. N=4–6 animals. n=44–102 investigated cells. *P<0.05, 
***P<0.001 vs sham cardiomyocytes. $P<0.05 vs TAC cardiomyocytes. Statistical significance was evaluated using Student t test in A through E and 2-way ANOVA 
followed by post-hoc Fisher LSD test for multiple comparisons in F.
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is important to note that JPIII treatment of the TAC car-
diomyocytes reduced SOCE down to the level observed 
in the sham-operated mice. These results demonstrate 
that Orai1 is a major participant in the exacerbated 
store-operated cation entry response observed in car-
diac hypertrophy.
C-dnO1 Mice Display Preserved 
Ventricular Function and Ca2+ Handling 
Under Physiological Condition
To examine the pathophysiological role of Orai1 in the 
heart, we generated a transgenic mouse line coexpress-
ing the human dominant-negative Orai1 channel (mis-
sense mutation R91W)16 and LacZ reporter using the 
Tet-Off inducible system (TetO-dn-Orai1R91W). To allow 
cardiomyocyte-specific expression, the TetO-dn-Orai-
1R91W strain was crossed with the α-MHC-tTA strain 
(Figure  2A), which showed heart specific expression 
in both ventricle and atrium compartment but not in 
other tissues.17,18 The double transgenic animal is here-
after referred to as C-dnO1. C-dnO1 offspring showed 
the expected Mendelian ratio and developed normally. 
No obvious in vivo or in vitro cardiac function differenc-
es were observed in α-MHC-tTA or TetO-dn-Orai1R91W 
mice compared with WT littermates, and then pooled 
as WT. Heart tissue and freshly isolated ventricular 
cardiomyocytes from C-dnO1 mice displayed blue-gal 
staining, which was absent in heart and cardiomyocytes 
from WT littermates (Figure 2B). Similarly, human Orai1 
mRNA was detected by quantitative reverse transcrip-
tion polymerase chain reaction only in ventricular tissue 
from C-dnO1 mice (Figure 2C). We further confirmed 
the overexpression of exogenous Orai1 with the clas-
sical multiple band pattern of human Orai1 protein in 
ventricle tissue by western blot (Figure 2D).19,20 In iso-
lated cardiomyocytes, Orai1 immunostaining revealed 
a sarcolemmal profile in WT cardiomyocytes, which 
was more pronounced in C-dnO1 cells (Figure  2E). 
Any potential compensation by other store-operated 
Ca2+ channel components (TRPC1 to -C6, STIM1-2 and 
Orai3 protein) was observed (Figure VIII in the online-
only Data Supplement). Cardiomyocytes from C-dnO1 
mice or from WT mice treated with 5 µM JPIII displayed 
reduced store-operated cation entry compared with WT 
cells (Figure 2F). It is important to note that Orai1 inhi-
bition by dn-Orai1R91W expression and JPIII application 
was not cumulative, indicating a complete blocking ef-
fect of dn-Orai1R91W mutant and equivalence between 
the two strategies. These data demonstrated that the 
Orai1R91W mutant was successfully expressed in heart 
and that selective SOCE inhibition was achieved.
To characterize the functional consequences of Orai1 
blockade on in vivo cardiac electromechanical function, 
echocardiography on anesthetized mice and electro-
cardiograms by telemetry on conscious mice were per-
formed at 2 to 3 months of age. Compared with WT 
littermate mice, C-dnO1 mice did not show any signs 
Table 2. Cardiac Function Analyzed by Echocardiography Under Stressed Condition
Echocardiographic 
Parameters
WT C-dnO1 P Value
Sham (N=17) TAC (N=15) Sham (N=15) TAC (N=16)
WT Sham vs 
WT TAC
WT Sham vs 
C-dnO1 Sham
C-dnO1 Sham  
vs C-dnO1 TAC
WT TAC vs 
C-dnO1 TAC
Heart rate, beats/min 523±12 539±10 490±13 494±11 0.33 0.047 0.81 0.008
Interventricular septum 
thickness in end diastole, mm
0.71±0.03 0.89±0.05 0.73±0.04 0.89±0.05 0.009 0.75 0.015 0.94
Interventricular septum 
thickness in end systole, mm
1.26±0.08 1.18±0.06 1.24±0.06 1.33±0.06 0.34 0.81 0.29 0.08
Left ventricular internal 
diameter in end diastole, mm
3.71±0.13 4.05±0.10 3.66±0.15 3.87±0.15 0.08 0.79 0.28 0.35
Left ventricular internal 
diameter in end systole, mm
2.21±0.15 3.04±0.13 2.17±0.18 2.51±0.18 0.0005 0.86 0.15 0.025
Left ventricular posterior wall 
in end diastole, mm
0.87±0.05 0.90±0.04 0.91±0.05 0.88±0.03 0.64 0.53 0.64 0.76
Left ventricular posterior wall 
in end systole, mm
1.24±0.07 1.13±0.05 1.23±0.06 1.25± 0.05 0.19 0.90 0.81 0.16
Left ventricular ejection 
fraction, %
77.6±2.4 55.4±3.1 77.4±3.1 70.2±3.7 0.0001 0.96 0.11 0.001
Left ventricular fractional 
shortening, %
41.9±2.4 25.1±1.9 42.2±2.9 35.9±2.7 0.0001 0.94 0.09 0.003
End-diastolic volume, mL 0.13±0.01 0.17±0.01 0.13±0.01 0.15±0.02 0.04 0.99 0.30 0.30
End-systolic volume, mL 0.035±0.005 0.077±0.009 0.036±0.006 0.052±0.010 0.0003 0.93 0.15 0.03
Stroke volume, mL 0.101±0.007 0.082±0.003 0.098±0.008 0.102±0.009 0.07 0.77 0.70 0.06
Statistical significance was evaluated using a 2-way ANOVA, then by a post hoc Fisher least significant difference test for multiple comparisons (reported P values). 
TAC indicates transverse aortic constriction; and WT, wild type.
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Figure 2. Cardiomyocyte-specific human dominant-negative Orai1 channel expression in mice (C-dnO1) does not alter in vivo and in vitro cardiac 
function under physiological condition. 
A, α-MHC-tTA/TetO-dn-Orai1R91W mice, named C-dnO1, were obtained by crossing a transgenic mouse line that coexpresses human dn-Orai1R91W and LacZ reporter 
under the control of a tetracycline response element (TRE) and another mouse line expressing tTA (tetracycline transactivator) gene under the regulation of a 
heart-specific α-MHC promoter. tTA binds the TRE promoter to drive the transcription of dn-Orai1R91W and LacZ genes specifically in the cardiomyocytes. B, Blue-
gal staining of a cross section of the heart and of adult ventricular cardiomyocytes from wild-type (WT; no color) and C-dnO1 mice (dark color). Scale bar, 1 mm. 
Magnification: X 200. C, Human Orai1 mRNA expression was determined by RT-qPCR in ventricle tissue from WT and C-dnO1 mice. mRNA levels were normalized 
to housekeeping genes and expressed as fold change of that determined in WT mice. N=6 animals. D, Representative western-blot of exogenous and endogenous 
Orai1 in ventricle tissue from WT and C-dnO1 mice. E, Representative confocal imaging (top panel) and quantification (bottom panel) of endogenous mouse Orai1 
and human dn-Orai1 proteins in adult ventricular cardiomyocytes from WT and C-dnO1 mice. (Continued )
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of cardiac dysfunction or alteration in overall pheno-
type, as assessed by morphometric (heart weight/body 
weight and heart weight/tibia length ratios) and echo-
cardiographic measurements (Tables 3 and 4 and Fig-
ures 2G and 2I). It is notable that C-dnO1 mice showed 
normal and conserved left ventricular (LV) contractility 
performance as measured by LV fractional shortening 
(Figure  2I). This was also observed in C-dnO1 mice 
at 6 months of age (Figure IX in the online-only Data 
Supplement). Of note, the tendency to observe lower 
heart rate in anesthetized C-dnO1 mice would point 
a slight improvement in systolic function in these mice 
compared with WT mice. In addition, cardiac electri-
cal activity evaluated by telemetric electrocardiograms 
from awake mice over 24 hours did not show statistical 
differences in heart rate, in conduction intervals, nor in 
ventricular activity (PR, QRS, and QT intervals) between 
groups (Figure X in the online-only Data Supplement).
Consistent with these whole animal observations, 
no major alterations were observed at cellular level. 
Freshly isolated LV cardiomyocytes from WT littermates 
and C-dnO1 mice did not present signs of cellular hy-
pertrophy as assessed by cellular area and membrane 
capacitance measurements (Table  5). Action potential 
waveforms, recorded using the whole-cell patch-clamp 
technique, were similar in both groups (Table 5). Like-
wise, we found no differences in cellular Ca2+ homeo-
stasis indicated by analysis of paced-[Ca2+]i transients 
or caffeine-induced [Ca2+]i transients using confocal line 
scan imaging of Fluo-4 loaded cardiomyocytes from WT 
littermates and C-dnO1 mice (Figures 2J through 2P). 
Similarly, no effects on the amplitude of [Ca2+]i tran-
sients, cell shortening, and the sarcoplasmic reticulum 
(SR) Ca2+ load were observed in isolated ventricular car-
diomyocytes from WT mice before and after perfusion 
with 5 µM of JPIII and of isolated ventricular cardiomyo-
cytes from mice treated for 3 weeks with JPIII (500 ng/
kg/min; Figure XI in the online-only Data Supplement). 
Moreover, no differences in RyR activity, measured as 
frequency and biophysical characteristics of spontane-
ous Ca2+ sparks (Figures XIIa through XIIe in the online-
only Data Supplement), or in diastolic Ca2+ levels, deter-
mined by Fura-2 ratio (ratio: 340/380; Figure XIIf in the 
online-only Data Supplement), were observed between 
cardiomyocytes of C-dnO1 mice and WT littermates.
Taken together, these data suggest that the inhibi-
tion of Orai1, under physiological conditions, does 
not directly modulate cardiac excitation-contraction 
coupling and does not cause any physiological conse-
quences.
Loss of Cardiomyocyte Orai1 Function 
Protects the Heart From Pressure 
Overload-Induced Systolic Dysfunction
To determine the functional relevance of Orai1 up-
regulation in the pathogenesis of cardiac hypertrophy, 
adult C-dnO1 mice were subjected to pressure over-
load by TAC. After 5 weeks of TAC, WT and C-dnO1 
mice showed a similar degree of cardiac hypertrophy 
as revealed by morphometric and echocardiographic 
analysis (Tables  1 and 2, Figures  3A through 3F). C-
dnO1 mice showed a similar increase in LV mass (esti-
mated by Penn formula, Figure 3D) and in interventric-
ular septum thickness in diastole (Figure 3E) compared 
with WT littermates. Moreover, C-dnO1 mice showed 
similar induction of hypertrophic marker gene expres-
sion such as Nppa and Acta1 after 5 weeks of TAC 
(Figure XIII in the online-only Data Supplement). It is 
interesting to note that Orai3 and STIM2 upregulation 
was reduced in C-dnO1 after TAC (Figures IIId and IIIf 
in the online-only Data Supplement). However, echo-
cardiographic analysis revealed protection from the 
development of systolic dysfunction in C-dnO1 mice 
compared with WT littermates. A significant 40% de-
crease in LV fractional shortening (Figure 3G) associ-
ated with markedly increased LV end systolic volume 
and decreased stroke volume (Table 2) was observed 
after TAC in WT mice. This was only reduced by 16% 
in C-dnO1 mice (Figure  3G) with preserved systolic 
and stroke volumes (Table 2).
Figure 2 Continued. N=3 animals. n=34–37 investigated cells. Scale bar, 25 μm. Insets represent 2-fold magnification of main images. F, Representative fluores-
cence traces of the Fura-2 decay phase upon Mn2+ addition in cardiomyocytes from WT (grey trace) and C-dnO1 (black trace) mice (left panel) and quantification 
of store-operated cation entry (right panel) for cardiomyocytes from WT and C-dnO1 mice in presence or absence of 5 µM JPIII. N=3–5 animals. n=26–85 investi-
gated cells. ***P<0.001 vs WT cardiomyocytes. G, Representative echocardiography left ventricular (LV) images in short axis and in M-mode from WT and C-dnO1 
mice. Averaged LV parameters, at baseline, obtained from analysis of echocardiograms: LV mass (H) and cardiac fractional shortening (FS, %) (I) in WT and C-dnO1 
mice. N=22–23 animals. J, Representative line-scan of [Ca2+]i transients in cardiomyocytes field-stimulated at 1 Hz and loaded with Fluo-4 from WT and C-dnO1 
mice. K, Average of [Ca2+]i transients amplitude (peak F/F0). L, Average of [Ca
2+]i transients decay time constant (ms). M, Average of the % of cell shortening. N, 
Representative line-scan of caffeine-evoked [Ca2+]i transients. O, Average of caffeine-evoked SR Ca
2+ load amplitude (peak F/F0). P, Average of caffeine-evoked SR 
Ca2+ load decay time constant (s). N=3–4 animals. n=62–77 investigated cells. Statistical significance was evaluated using Student t test except in F where 2-way 
ANOVA followed by post-hoc Fisher LSD test for multiple comparisons was used.
Table 3. Morphometric Analysis Under Basal Condition
Morphometric Analysis
Wild Type
 (N=18)
C-dnO1
 (N=18) P Value
Body weight, g 25.0±0.7 24.7±0.7 0.76
Heart weight, mg 158±4 162±5 0.54
Heart weight/body 
weight, mg/g
6.4±0.1 6.6±0.1 0.17
Tibia length, mm 17.3±0.1 17.3±0.1 0.99
Heart weight/tibia length, 
mg/mm
9.1±0.2 9.4±0.2 0.30
Statistical significance was evaluated using a Student t test (reported P 
values).
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It is important to note that we observed less intersti-
tial collagen deposition using Picosirius red staining in 
heart sections from C-dnO1 versus WT mice compared 
with their respective sham-operated counterparts (Fig-
ure 3H). This is correlated in C-dnO1 mice with less in-
duction of fibrillar type III collagen (Col3a1) transcripts 
after 5 weeks of TAC (Figure 3I).
At a cellular level, planimetric cell area measure-
ments (Figure 3J) showed similar hypertrophy in isolated 
ventricular cardiomyocytes from WT littermates and C-
dnO1 mice after TAC. Moreover, the prolongation of ac-
tion potential duration (APD), electrophysiological stig-
mata of cardiac hypertrophy, is similarly observed in WT 
and C-dnO1 mice after TAC (WT sham cardiomyocytes: 
APD [in ms] at 20%: 1.44±0.08, at 50%: 5.02±0.47, 
at 90%: 34.5±6.0 [n=11]; WT TAC cardiomyocytes: 
at 20%: 2.89±1.0, at 50%: 11.89±4.26, at 90%: 
76.77±9.84 [n=19]; C-dnO1 TAC cardiomyocytes: 
APD at 20%: 3.55±1.48, at 50%: 10.71±3.89, at 
90%: 91.07±25.79 [n=11]), P<0.001 versus WT sham. 
However, the exacerbated store-operated cation entry 
found in WT after TAC (Figure 1) was abolished in C-
dnO1 mice (Figure 3K).
Collectively, these results suggest that inhibiting 
Orai1 function in the heart could be beneficial after in-
sult by protecting it against systolic dysfunction.
Loss of Cardiomyocyte Orai1 Function 
Prevents the Ca2+ Cycling Mishandling 
and Pyk2/MEK/ERK Pathway Activation 
After TAC
To obtain cellular mechanistic insights, we next exam-
ined the modulation of Ca2+ signaling after TAC in WT 
and C-dnO1 mice. Figure 4A illustrates confocal line-
scan images of steady-state paced-[Ca2+]i transients 
of isolated ventricular cardiomyocytes from the differ-
ent groups. After TAC, the [Ca2+]i transients amplitude 
(Figure  4B) was significantly decreased together with 
a prolonged decline (Figure 4C) and a reduction in cell 
shortening (Figure 4D) in WT cardiomyocytes. All these 
TAC-induced alterations were prevented in cardiomyo-
cytes from C-dnO1 mice (Figures 4A through 4D). The 
reduction in [Ca2+]i transients and myocyte shortening 
in WT mice after TAC were attributable to a decrease 
in SR Ca2+ load, as assessed by both peak decrease and 
decay deceleration of the caffeine-induced [Ca2+]i tran-
sients (Figures 4E through 4G). It is remarkable that car-
diomyocytes from C-dnO1 mice fully rescued this phe-
notype after TAC (Figures 4E through 4G). Consistent 
with the Orai1 upregulation relevance after hypertro-
phic insult, the F340/380 ratio recorded with Fura-2 is 
decreased after TAC when Orai1 is inhibited (Figure XIV 
in the online-only Data Supplement).
Consistent with the decreased SR Ca2+ load, the 
reduction in SERCA2a at mRNA and protein levels in 
WT ventricles was prevented in C-dnO1 mice after TAC 
(Figure  4H and 4I and Figure XVa in the online-only 
Data Supplement).
No changes in CaMKII and calcineurin activities, 
Ca2+-dependent pathways involved in the pathogen-
esis of cardiac hypertrophy, as well as their targets 
(RyR and PLB phosphorylation states) were found after 
TAC in both conditions (Figure XVb through XVe in the 
online-only Data Supplement). However, as previously 
demonstrated in neonatal cardiomyocytes,4 we found a 
significant increase in ERK1/2 activity and expression af-
ter TAC, which was totally prevented in ventricles from 
C-dnO1 mice (Figure 5A). Western blot analysis of the 
Table 5. In Vitro Functional Parameters Under Basal Condition
In Vitro Functional 
Parameters
Wild Type
 (N=3)
C-dnO1
 (N=3) P Value
Cellular area, µm2 3087±109 3208±85 0.37
(n=107) (n=129)  
Membrane capacitance, pF 154±14 150±14 0.85
(n=15) (n=23)  
Action potential duration, 
ms (at 20%, 50%, and 
90%)
1.48±0.13 1.56±0.16 0.72
5.11±0.70 5.15±0.52 0.96
42.75±7.08 33.77±2.10 0.16
(n=15) (n=23)  
Statistical significance was evaluated using a Student t test (reported P 
values).
Table 4. Cardiac Function Analyzed by Echocardiography Under Basal 
Condition
Echocardiographic 
Parameters
Wild Type
 (N=23)
C-dnO1
 (N=22) P Value
Heart rate, beats/min 546±17 498±13 0.03
Interventricular septum 
thickness in end diastole, mm
0.70±0.02 0.70±0.02 0.99
Interventricular septum 
thickness in end systole, mm
1.09±0.03 1.04±0.02 0.18
Left ventricular internal 
diameter in end diastole, mm
3.80±0.06 3.83±0.07 0.75
Left ventricular internal 
diameter in end systole, mm
2.37±0.06 2.47±0.07 0.28
Left ventricular posterior wall 
in end diastole, mm
0.78±0.02 0.81±0.03 0.41
Left ventricular posterior wall 
in end systole, mm
1.07±0.03 1.07±0.04 0.99
Left ventricular ejection 
fraction, %
74.1±1.1 71.5±1.2 0.12
Left ventricular fractional 
shortening, %
37.8±0.9 35.6±1.0 0.11
End-diastolic volume, mL 0.14±0.01 0.15±0.01 0.48
End-systolic volume, mL 0.04±0.01 0.04±0.01 0.99
Stroke volume, mL 0.10±0.01 0.10±0.01 0.99
Statistical significance was evaluated using a Student t test (reported P 
values).
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upstream signaling pathway showed that TAC-induced 
increases in MEK and Pyk2 (Figure 5B) expression and 
phosphorylation were prevented in C-dnO1 mice (Fig-
ure 5B), suggesting that a Pyk2/MEK/ERK cascade is as-
sociated with the observed Orai1 inhibition-dependent 
protective effects.
Similarly and consistent with previous studies,21–23 
in neonatal rat ventricular cardiomyocytes exposed for 
48 hours to 100 µM phenylephrine, which induced 
increases in prohypertrophic genes such as Nppa and 
Nppb (Figure XVIa in the online-only Data Supplement) 
and in Orai1 expression (Figure XVIb and XVIc in the 
online-only Data Supplement), cotreatment during the 
past 24 hours with a Pyk2 inhibitor PF-04520440 (5 
µM) or JPIII (5 µM) prevented the increased Pyk2 phos-
phorylation (Figure 5C) and reduced the downregula-
tion of SERCA2a mRNA expression (Figure 5D). In this 
in vitro model, the phenylephrine-induced increased 
ERK phosphorylation was not changed after Pyk2 and 
Orai1 inhibition (Figure XVId in the online-only Data 
Supplement).
Overall, our results suggest that preserved cardiac 
inotropy function by cardiomyocyte Orai1 inhibition 
is related to prevention of altered Ca2+ cycling and 
Figure 3. Depressed systolic function observed in wild-type mice 5 weeks after TAC is prevented in C-dnO1 mice. 
 A, Representative whole hearts from wild-type (WT) and C-dnO1 sham or transverse aortic constriction (TAC)-operated mice. Scale bar, 1 cm. B, Representative 
echocardiography images of LV in short-axis and in M-mode from WT and C-dnO1 sham or TAC mice. C, Morphometric analysis from WT and C-dnO1 sham or TAC 
mice. N=15–16 animals. D through G, LV parameters obtained from analysis of echocardiograms: LV mass (D), interventricular septal thickness at end of diastole 
(IVSd) and systole (IVSs) (E), LV internal diameter at end of diastole (LVIDd) and systole (LVIDs) (F) and cardiac FS % (G) in WT and C-dnO1 mice after TAC. N=15–17 
animals. *P<0.05, **P<0.01, ***P<0.001 vs respective sham mice. $P<0.05 vs WT TAC mice. H, Left panel: representative images of interstitial collagen deposition 
in heart tissue sections stained with Picrosirius red from WT and C-dnO1 sham or TAC mice. Scale bar, 100 µm. Right panel: analysis of interstitial collagen staining 
as a percentage of tissue area. N=5–6 animals. ***P<0.001 vs sham mice. $$P<0.01 vs WT TAC mice. I, Type I collagen (Col1a1) and type III collagen (Col3a1) mRNA 
expression was determined by RT-qPCR in ventricle tissue from WT and C-dnO1 sham or TAC mice. mRNA levels were normalized to housekeeping genes and 
expressed as fold change of that determined in WT sham mice. N=6 animals. ***P<0.001 vs respective sham mice. $P<0.05 vs WT TAC mice. J, Left panel: repre-
sentative conventional microscopy images of WT and C-dnO1 cardiomyocytes from sham and TAC mice. Scale bar, 50 μm. Right panel: cell size (µm2) measured by 
planimetry. N=3–4 animals. n=68–131 investigated cells. ***P<0.001 vs respective sham mice. K, Representative fluorescence traces (left panel) and quantification 
(right panel) of the Fura-2 decay phase upon Mn2+ addition in cardiomyocytes from C-dnO1 sham and TAC mice. N=3 animals. n=64–68 investigated cells. Statistical 
significance was evaluated using 2-way ANOVA followed by post-hoc Fisher LSD test for multiple comparisons, except in K where Student t test was used.
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SERCA2a expression associated with Pyk2 and/or MEK/
ERK pathway.
Orai1 Inhibition by JPIII Infusion Protects 
the Heart From Pressure Overload-
Induced Systolic Dysfunction
Next, we aimed to determine whether the effect of the 
C-dnO1 construct could be recapitulated by a transla-
tionally relevant small molecule inhibitor approach. The 
JPIII pharmacokinetic data (Figure VII in the online-only 
Data Supplement) supported the suitability of JPIII for 
this purpose. The JPIII stock solution was detectable by 
liquid chromatography-mass spectrometry as a single 
ion peak at 321.2 m/z with a characteristic UV chro-
matogram for the extracted peak (Figure XVIIa in the 
online-only Data Supplement). JPIII was stable at physi-
ological temperature for 28 days and not degraded by 
the material used in the osmotic mini-pumps compared 
with the stock solution alone (Figures XVIIb and XVIIc in 
the online-only Data Supplement). Dose finding stud-
ies (Figure XVIId in the online-only Data Supplement) 
demonstrated detection of JPIII in serum 15 minutes af-
ter administration of 0.72 mg/kg/day (equivalent to an 
Figure 4. The Ca2+ cycling mishandling observed in wild-type mice 5 weeks after TAC is restored in C-dnO1 mice.
A, Representative line-scan of [Ca2+]i transients in cardiomyocytes field-stimulated at 1 Hz and loaded with Fluo-4 from wild-type (WT) and C-dnO1 sham or 
transverse aortic constriction (TAC) mice. B, Average of [Ca2+]i transients amplitude (peak F/F0). C, Average of [Ca
2+]i transients decay time constant (ms). D, Aver-
age of the % of cell shortening. E, Representative line-scan of caffeine-evoked [Ca2+]i transients. F, Average of caffeine-evoked SR Ca
2+ load amplitude (peak F/F0). 
G, Average of caffeine-evoked SR Ca2+ load decay time constant (s). N=3–4 animals. n=50–75 investigated cells. *P<0.05, **P<0.01 vs WT sham mice. $P<0.05, 
$$P<0.01, $$$P<0.001 vs WT TAC mice. H, SERCA2a mRNA expression was determined by RT-qPCR in ventricle tissue from WT and C-dnO1 sham or TAC mice after 
5 weeks. mRNA levels were normalized to housekeeping genes and expressed as fold change of that determined in sham mice. N=5–6 animals. **P<0.01 vs WT 
sham mice. I, Representative western-blot and quantification of SERCA2a protein in ventricle tissue from sham and TAC mice. Protein levels were normalized by β-
actin and expressed as fold change of that determined in sham mice. N=4–6 animals. *P<0.05 vs WT sham mice. Statistical significance was evaluated using 2-way 
ANOVA followed by post-hoc Fisher LSD test for multiple comparisons.
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Figure 5. Increased MEK/ERK and Pyk2 activity observed in wild-type mice 5 weeks after TAC is blunted in C-dnO1 mice.
A and B, Representative western-blots and quantifications of P-ERK1/2 and Total-ERK1/2 (A),of P-Pyk2 and Total-Pyk2 (B) and of P-MEK and Total-MEK (B) in ventricle 
tissue from sham and transverse aortic constriction (TAC) mice. Protein levels were normalized by β-actin and expressed as fold change of that determined in sham mice. 
N=4–7 animals. *P<0.05, **P<0.01, ***P<0.001 vs wild type (WT) sham mice. $P<0.05, $$P<0.01 vs WT TAC mice. C, Representative western-blots and quantifications 
of P-Pyk2 and Total-Pyk2 in ctrl or phenylephrine-treated neonatal rat ventricular cardiomyocytes (NRVMs) in presence of Pyk2 inhibitor (PF-04520440) or JPIII. Phos-
phorylation levels were normalized by Total-Pyk2 expression and expressed as fold change of that determined in ctrl NRVMs. D, Relative SERCA2a mRNA expression was 
determined by RT-qPCR in ctrl or phenylephrine-treated NRVMs in presence of PF-04520440 or JPIII. mRNA levels were normalized to housekeeping genes and expressed 
as fold change of that determined in ctrl NRVMs. *P<0.05, **P<0.01, ***P<0.001 vs ctrl NRVMs. $P<0.05, $$P<0.01 vs phenylephrine-treated NRVMs. Statistical signifi-
cance was evaluated using 2-way ANOVA followed by post-hoc Fisher LSD test for multiple comparisons except in C where 1-way ANOVA was used.
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infused dose of 500 ng/kg/min via osmotic mini-pump). 
Pilot studies dosing C57BL6/J mice with JPIII at 500 ng/
kg/min via subcutaneous osmotic mini-pump infusion 
for 28 days demonstrated no adverse effects on the 
animals. Animal weights (Figure XVIIe in the online-only 
Data Supplement), systolic and diastolic blood pressure 
measured in awake restrained mice by tail cuff plethys-
mography (Figure XVIIf in the online-only Data Supple-
ment), and the heart weight–body weight ratio (Figure 
XVIIg in the online-only Data Supplement) were similar 
between the JPIII and vehicle infused groups. Blood sam-
pling from the saphenous vein on day 14 of the infusion 
confirmed presence of JPIII in the serum (Figure XVIIh 
in the online-only Data Supplement) and explant of the 
pumps at the end of the experiment (Figure XVIIh inset 
in the online-only Data Supplement) confirmed success-
ful delivery. A toxicology screening study performed in 
CD-1 outbred mice infused with JPIII (500 ng/kg/min) 
or vehicle via osmotic mini-pump for 28 days showed 
no major toxic effect on the animals; in particular no 
changes in total or differential white cell counts were 
observed (Figure XVIII in the online-only Data Supple-
ment). JPIII is therefore a suitable novel tool compound 
for testing the hypothesis in murine models that can be 
effectively delivered by osmotic mini-pump infusion.
To confirm the potential therapeutic benefit of Orai1 
inhibition after hypertrophic insult, WT mice were sub-
jected to 5 weeks TAC and then, randomly assigned to 
constant delivery of vehicle (DMSO) or JPIII (at 500 ng/
kg/min) by osmotic mini-pump for 3 weeks. This ap-
proach showed that cardiac hypertrophy was not af-
fected in JPIII-treated mice compared with vehicle-treat-
ed WT animals (Figure  6A through 6D, Tables  6 and 
7). However, the progressive decline in systolic function 
measured by LV fractional shortening (%) was blunted 
after JPIII treatment (Figure 6E and 6F, Table 7). Of note, 
vehicle or JPIII treatment did not alter heart morphol-
ogy or ventricular function of sham-operated animals 
(Table 6 and 7, Figure XIX in the online-only Data Sup-
plement). However, we observed complete prevention 
of the increase in fibrillar type I and III collagens (Col1a1 
and Col3a1) transcripts in JPIII-treated hearts compared 
with vehicle-treated hearts after TAC (Figure 7A).
At the cellular level, this effect was associated with 
preserved SR Ca2+ load (Figure 7B) correlating with rescue 
of SERCA2a expression (Figure 7C) and reduced Pyk2, 
MEK and ERK1/2 activities (Figure 7D) from JPIII-treated 
mice after TAC. The data suggest that JPIII, like C-dnO1, 
protects against specific aspects of systolic dysfunction.
DISCUSSION
Our results suggest that genetic or pharmacologic in-
hibition of cardiomyocyte Orai1 is not instrumental 
in regulating excitation-contraction coupling and car-
diac function in the adult mouse heart but that it is 
cardioprotective against pressure overload-induced sys-
tolic dysfunction without affecting cardiac hypertrophy 
itself. These beneficial effects were associated with a 
reduction in the extent of interstitial fibrosis and pre-
vention of Ca2+ homeostasis alterations. In addition, 
we showed that selective Orai1 channel blockade is a 
potential effective therapeutic for systolic dysfunction 
after chronic pressure overload.
The existence and contribution of SOCE is well es-
tablished in the developing heart for regulating dia-
stolic Ca2+ homeostasis and cardiac growth.7 Orai1 ex-
pression is low in adult mouse heart and the functional 
significance of SOCE in the normal adult heart is not 
well defined. Under physiological conditions, we found 
that cardiomyocyte-specific functional inhibition of 
Orai1 channels in C-dnO1 mice had little impact, with 
normal LV contractility performance until 6 months of 
age, similar to what has previously been demonstrated 
with global heterozygous Orai1+/- mice10 alongside nor-
mal electrical function. At a cellular level, no alterations 
of action potential or Ca2+ homeostasis were observed 
although the SOCE was significantly decreased. Con-
sistent with data obtained in C-dnO1 mice, acute or 
chronic pharmacological Orai1 inhibition by JPIII also 
has no impact on excitation-contraction coupling. 
Thus, Orai1 activity makes no contribution to the elec-
tromechanical function of normal ventricular cardio-
myocytes. This is consistent with previous results using 
a nonselective Orai1 blocker or Orai1 knock-down in 
feline and rat hearts.24–26 Our results on excitation-
contraction coupling are not surprising given the slow 
Orai1 activation kinetic (10s to 100s) because of the 
need for STIM translocation in non-excitable cells.27,28 
This is not compatible to fast excitation-contraction 
coupling (ms ranged) even if ultra-rapid (in a range of 
ms) activation of SOCE has been described in skeletal 
muscle.29 On the other hand, double TRPC1/C4 KO 
mice exhibited lower diastolic and systolic Ca2+ con-
centrations, under basal conditions.30 By contrast, en-
hanced cardiac pump function was found in cardiac 
specific dn-TRPC4 mice with increased myocyte frac-
tional shortening and peak [Ca2+]i transients
31 suggest-
ing that TRPC subfamily, but not Orai1, fine tunes Ca2+ 
cycling in beating adult mice cardiomyocytes.
Our combination of genetic and pharmacologic 
Orai1 inhibition approaches revealed a contribution of 
cardiomyocyte Orai1 channels in pressure overload-
induced systolic dysfunction. Consistent with previous 
studies,5,12 Orai1 expression was increased after 5 weeks 
of TAC, exacerbating SOCE. Contrasting with compen-
sated hypertrophic animal models that lack alteration of 
systolic function as assessed by the absence of LV frac-
tion shortening modification,12,24,32 our model of pres-
sure overload-induced cardiac hypertrophy associated 
with ventricular dysfunction produces a more severe 
phenotype and lacks upregulation of STIM1 expression. 
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Nevertheless, we found a significant upregulation of 
STIM2 after TAC. This upregulation is also reduced in C-
dnO1 mice after TAC. STIM2 is known to participate to 
the SOCE machinery33,34 and have a crucial function in 
inducing the activated conformation of STIM1 causing 
STIM1/Orai1 coupling and enhancement of Orai1 func-
tion.35 This allows us to suggest that enhanced Orai1-
dependent Ca2+ entry after hypertrophic insult is poten-
tially dependent on STIM2, directly or indirectly, which 
is a new concept worthy of future further investigation.
The direct contribution of Orai1-dependent Ca2+ entry 
to the hypertrophic process is still under debate. Indeed, 
in vitro data showed that neurohormonal stimulation in-
creased Orai1 expression11 and that Orai1 silencing com-
pletely abrogated the hypertrophic signal by inhibiting 
CaMKII and the ERK1/2 signaling pathway4,11 highlighting 
a protective effect of inhibiting Orai1 after hypertrophic 
insults. However, global heterozygous Orai1+/- mice sub-
mitted to TAC had greater dilation of left ventricle and 
decline in ventricular function than WT mice suggesting 
a deleterious effect of constitutive Orai1 haploinsufficien-
cy.10 Here, while the pathological changes in ventricular 
geometry were similar between WT and cardiomyocyte 
C-dnO1 mice after TAC, C-dnO1 mice exhibited preserved 
systolic function. The fact that inhibiting Orai1 function in 
the heart could be beneficial after insult clarifies the situ-
ation and provides an important breakthrough, suggest-
ing that the global Orai1+/- is related to either constitutive 
deletion during development or systemic alteration and 
not to cardiac specific alteration in the adult.
In our conditions, inhibiting Orai1 did not prevent 
the development of cardiac hypertrophy. This may be 
Figure 6. Orai1 inhibition by JPIII protects the heart from pressure overload-induced ventricular systolic dysfunction.
A, Morphometric analysis from sham and transverse aortic constrction (TAC)-operated mice. N=4–5 animals. ***P<0.001 vs respective sham mice. Statistical 
significance was evaluated using 2-way ANOVA followed by post-hoc Fisher LSD test for multiple comparisons. B and C, Time-dependent effect of vehicle- and 
JPIII-treatment on LV mass (B) and interventricular septal thickness at end diastole and systole (C) in sham and TAC mice. N=5 animals. D, Time-dependent effect 
of vehicle- and JPIII-treatment on LV internal diameter at end diastole and systole in sham and TAC mice. N=5 animals. E and F, Time-dependent effect of vehicle- 
and JPIII-treatment on LV FS (%) in sham (left panel) and TAC-operated (right panel) mice. N=5 animals. Statistical significance was evaluated using 2-way repeated 
measures ANOVA. ***P<0.001 vs before TAC or 5 weeks after TAC. $$P<0.01 vs vehicle-treated mice after 8 weeks of TAC. F, Right panel: % of LV FS for each 
mice presented in E obtained by subtracting FS after and before treatment. FS indicates fractional shortening; interventricular septal thickness at end of diastole; 
IVSd, interventricular septal thickness at end of diastole; IVSs; interventricular septal thickness at end of diastole systole; JPIII, 4-(2,5-dimethoxyphenyl)-N-[(pyridin-
4-yl)methyl] aniline; LV, left ventricular; and LVIDd, LV internal diameter at end of diastole.
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because of an increased TRPC6 expression following 
TAC, as TRPC6 has been identified as a key player in-
fluencing the development of hypertrophy and heart 
disease by inducing calcineurin/NFAT signaling.36–38 
Supportive of this concept, increased calcineurin activ-
ity after TAC was similar in WT and C-dnO1 mice sug-
gesting that Orai1 is not instrumental in a calcineurin-
dependent hypertrophic process in this pathology. The 
concept that prevention of hypertrophy is beneficial in 
cardiac disease is now controversial. Indeed, some re-
ports showed that hypertrophy blockade may be det-
rimental.39 In the same way, cardiac STIM1 silencing in 
mice impairs adaptive hypertrophy and promotes the 
transition to HF.40
Moreover, we highlighted that the preserved ven-
tricular function observed in C-dnO1 mice is related to 
maintaining normal Ca2+ cycling. Indeed, all Ca2+ sig-
naling alterations observed in cardiomyocytes from WT 
TAC animals, which includes decreased [Ca2+]i transient 
amplitude, slowing of the systolic [Ca2+]i transients as-
sociated with lower Ca2+ SR load and decreased level 
of SERCA2a expression and depressed cellular con-
tractility were prevented in ventricular cardiomyocytes 
from C-dnO1 mice.
Analysis of upstream signaling pathways revealed 
that a sustained increase in intracellular Ca2+ through 
Orai1 is associated with Pyk2 (a member of the FAK 
family of protein tyrosine kinases)/MEK/ERK signaling 
pathway overactivation. This is consistent with upreg-
ulation and activation of Pyk2 in the pathogenesis of 
LVremodeling and HF41–43 and corroborates that in vitro 
Orai1 silencing or inhibition has been associated with 
a reduction of ERK1/2 and Pyk2 activity after phenyl-
ephrine treatment in neonatal cardiomyocytes4 and in 
glioma cells.44 In addition, cumulative evidence sug-
gests that Pyk2 and ERK1/2 negatively regulate SER-
CA2a expression in neonatal, HL-1, and adult cardio-
myocytes,21,23,45–47 and arterial smooth muscle.22 Our in 
vivo and in vitro results suggest that after hypertrophic 
insults, Orai1 inhibition is associated with blunted Pyk2 
activation, which reduces SERCA2a downregulation, 
possibly in combination with MEK/ERK pathway.
Cardiac fibrosis remodeling is a major characteristic 
of pathological cardiac hypertrophy leading to a de-
crease in myocardial compliance and changes in electri-
cal conduction.48 We showed that C-dnO1 mice after 
hypertrophic stress exhibited less interstitial fibrosis de-
position and less type III collagen expression than WT 
Table 6. Morphometric Analysis 8 Weeks After TAC in Vehicle and JPIII-Treated Mice
Morphometric Analysis
Vehicle JPIII P Value
Sham (N=4) TAC (N=5) Sham (N=4) TAC (N=5)
Vehicle Sham 
vs Vehicle TAC
Vehicle Sham 
vs JPIII Sham
JPIII Sham vs 
JPIII TAC
Vehicle TAC vs 
JPIII TAC
Heart weight/body weight, mg/g 7.4±0.2 9.5±0.3 6.9±0.2 9.4±0.3 0.0001 0.24 0.0001 0.79
Heart weight/tibia length, mg/mm 10.7±0.3 14.4±0.3 10.3±0.7 13.3±0.4 0.0001 0.55 0.0001 0.08
Statistical significance was evaluated using a 2-way ANOVA, then by a post hoc Fisher least significant difference test for multiple comparisons (reported P values). 
JPIII indicates 4-(2,5-dimethoxyphenyl)-N-[(pyridin-4-yl)methyl]aniline; and TAC, transverse aortic constriction.
Table 7. Cardiac Function Analyzed by Echocardiography 8 Weeks After TAC in Vehicle and JPIII-Treated Mice
Echocardiographic 
Parameters
Vehicle JPIII P Value
Sham (N=4) TAC (N=5) Sham (N=4) TAC (N=5)
Vehicle Sham 
vs Vehicle TAC
Vehicle Sham 
vs JPIII Sham
JPIII Sham 
vs JPIII TAC
Vehicle TAC 
vs JPIII TAC
Heart rate, beats/min 547±16 534±16 530±16 543±15 0.57 0.48 0.57 0.68
Interventricular septum 
thickness in end systole, mm
1.40±0.05 1.41±0.11 1.52±0.10 1.67±0.16 0.95 0.51 0.39 0.13
Left ventricular internal 
diameter in end diastole, mm
3.45±0.08 4.40±0.16 4.03±0.21 4.41±0.14 0.0007 0.03 0.96 0.11
Left ventricular internal 
diameter in end systole, mm
1.79±0.16 3.27±0.12 2.32±0.11 2.82±0.17 0.0001 0.029 0.029 0.036
Left ventricular posterior wall 
in end diastole, mm
1.12±0.05 1.12±0.15 0.98±0.11 1.26±0.12 0.99 0.45 0.12 0.40
Left ventricular posterior wall 
in end systole, mm
1.59±0.13 1.38±0.15 1.45±0.08 1.56±0.07 0.22 0.43 0.51 0.26
Left ventricular ejection 
fraction, %
84.9±2.8 56.9±1.3 81.4±0.9 71.2±3.8 0.0001 0.38 0.015 0.001
End-diastolic volume, mL 0.11±0.007 0.21±0.022 0.15±0.012 0.17±0.02 0.001 0.16 0.44 0.12
End-systolic volume, mL 0.034±0.012 0.089±0.008 0.030±0.004 0.044±0.011 0.001 0.78 0.31 0.003
Stroke volume, mL 0.093±0.004 0.121±0.013 0.120±0.021 0.126±0.005 0.13 0.16 0.73 0.76
Statistical significance was evaluated using a 2-way ANOVA, then by a post hoc Fisher least significant difference test for multiple comparisons (reported P values). 
JPIII indicates 4‐(2,5‐dimethoxyphenyl)‐N‐(pyridin‐4‐ylmethyl)aniline; and TAC, transverse aortic constriction.
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mice. The cardioprotective effect of Orai1 inhibition is 
associated with restored Ca2+ homeostasis after cardiac 
insult but seems to also depend on fibrosis. According-
ly, some studies had proved a link between Orai1 and 
fibrosis.10,49,50 More important, it has been demonstrat-
ed that human ventricular fibroblasts from HF patients 
had increased collagen secretion capacity, which was 
related to increase in expression of Orai1 and SOCE.50
To explore the potential therapeutic relevance of 
the approach, Orai1 small-molecule inhibition was ap-
plied after hypertrophic insult and the development 
of left ventricular systolic dysfunction. In keeping with 
the results obtained in C-dnO1 mice, this translational 
approach showed that the progressive decline in ven-
tricular function in vehicle-treated mice was prevented 
with JPIII treatment, without affecting cardiac hyper-
trophy. No fibrosis was observed when Orai1 is inhib-
ited pharmacologically. Thus, we speculate an effect of 
JPIII in additional cell types in the heart, such as cardiac 
fibroblasts.
At a cellular level, the protective effect of JPIII as for 
C-dnO1 mice was associated with maintained SR Ca2+ 
Figure 7. Orai1 inhibition by JPIII protects the heart from pressure overload-induced ventricular Ca2+ mishandling.
A, Type I collagen (Col1a1) and type III collagen (Col3a1) mRNA expression was determined by RT-qPCR in ventricle tissue from WT sham or TAC mice treated or 
not with JPIII. mRNA levels were normalized to housekeeping genes and expressed as fold change of that determined in sham mice. N=4–5 animals. *P<0.05 vs re-
spective sham mice, $P<0.05 vs vehicle-treated TAC mice. B, Average of caffeine-evoked SR Ca2+ load amplitude (peak F/F0). N=3–4 animals. n=37–55 investigated 
cells. *P<0.05 vs sham mice, $P<0.05 vs vehicle-treated TAC mice. C, SERCA2a mRNA expression was determined by RT-qPCR in ventricle tissue from sham or 
TAC mice treated or not with JPIII. mRNA levels were normalized to housekeeping genes and expressed as fold change of that determined in sham mice. N=4–5 
animals. *P<0.05 vs sham mice. D, Representative western-blots and quantification of phosphorylated over total forms of Pyk2, MEK and ERK1/2 in ventricular 
cardiomyocytes from sham and TAC mice treated or not with JPIII, expressed as fold change of that determined in vehicle-treated sham mice. N=3–4 animals. 
**P<0.01, ***P<0.001 vs sham mice. *P<0.05, $$P<0.01 vs vehicle-treated TAC mice. Statistical significance was evaluated using 2-way ANOVA followed by post-
hoc Fisher LSD test for multiple comparisons. TAC indicates transverse aortic constriction.
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load, normal SERCA2a expression and normal Pyk2/
MEK/ERK1/2 activity.
These data suggest that targeted inhibition of Orai1 
channels might be a promising strategy for maintaining 
contractility reserve after TAC. Although we did not ob-
serve immune compromise in our CD-1 toxicity study, 
given the important functional role of Orai1 in the im-
mune system, it is an important consideration for this 
therapeutic approach moving forward.
It should be recognized that biochemical approaches 
such as western-blot and immunofluorescence have 
limited capabilities for proving the expression of a low 
abundance membrane protein such as Orai1 in a spe-
cific cell type such as cardiac myocytes. The antibody 
quality needs to be extremely high, but this has proven 
difficult to achieve for Orai1 through commercial sup-
pliers or efforts of independent scientific groups such 
as ours. After extensive searching and validation, we 
have been able to provide evidence for cardiac myocyte 
Orai1 using these approaches, but we caution against 
conclusions based only on these data. Mass spectrome-
try capabilities have improved in recent years and could, 
in principle, provide complementary evidence. How-
ever, there are problems detecting natively-expressed 
low-abundance target proteins if they are difficult to 
solubilize and purify from complex samples; as is the 
case with membrane proteins such as Orai1 in cardiac 
myocytes. We performed mass spectrometry analysis 
after immunoprecipitation of Orai1 but could not de-
tect Orai1 peptide even from whole heart, despite other 
expected peptides being readily resolved (unpublished 
data). Importantly, therefore, we took advantage of ad-
ditional independent methods. A Mn2+ flux technique 
was applied to isolated cardiac myocytes, enabling us 
to demonstrate the presence of function Orai1 protein 
both using our newly-developed specific blocker of 
Orai1 (JPIII) and cardiac myocyte-specific expression of 
mutant dominant-negative Orai1 developed (C-dnO1). 
We went on to use C-dnO1 for extensive in vivo stud-
ies. These approaches have enabled exciting privileged 
insight, clarifying the importance of Orai1 in myocytes 
and potentially motivating important new therapeutic 
strategies for problems of HF, which we suggest should 
seek partial inhibition, not ablation, of Orai1.
Collectively, our findings underscore the concept 
that Orai1 might be a stress response molecule that 
is upregulated in cardiac hypertrophy, associated with 
Pyk2 and/or MEK/ERK cascade overactivation and SER-
CA2a downregulation, leading to depressed Ca2+ cy-
cling and ventricular dysfunction as part of a maladap-
tive response.
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